Realm Therapeutics Plc (RLM)’s Financial Results Comparing With Onconova Therapeutics Inc. (NASDAQ:ONTX)

Both Realm Therapeutics Plc (NASDAQ:RLM) and Onconova Therapeutics Inc. (NASDAQ:ONTX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Realm Therapeutics Plc N/A 0.00 N/A 0.00 0.00
Onconova Therapeutics Inc. 1.31M 13.88 21.13M -16.25 0.00

Demonstrates Realm Therapeutics Plc and Onconova Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 provides us Realm Therapeutics Plc and Onconova Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Realm Therapeutics Plc 0.00% 0% 0%
Onconova Therapeutics Inc. -1,612.98% 0% -126.3%

Institutional & Insider Ownership

Realm Therapeutics Plc and Onconova Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 54.1%. On the other hand, insiders owned about 4.95% of Onconova Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Realm Therapeutics Plc -32.55% -28.21% 0% 0% 0% -70.18%
Onconova Therapeutics Inc. -16.59% -37.59% -45.15% -56.3% -83.33% -83.91%

For the past year Realm Therapeutics Plc’s stock price has smaller decline than Onconova Therapeutics Inc.

Summary

On 5 of the 8 factors Realm Therapeutics Plc beats Onconova Therapeutics Inc.

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc is based in London, the United Kingdom.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companyÂ’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; a license agreement with SymBio Pharmaceuticals Limited; and a strategic collaboration with Cellectar Biosciences, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.